Randomised phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to down-stage large oestrogen receptor positive breast cancer (ANZ 1401 ELIMINATE)

* Dataset of 134 women with ER-positive, HER2-negative grade 2/3 invasive breast cancer greater than 20mm. *Randomised 2:1 to receive either standard neoadjuvant chemotherapy concurrently with aromatase inhibitor (89 patients) or standard neoadjuvant chemotherapy only (45 patients) for 18-24 weeks. * Rate of downstaging to pathologic stage 0 or 1A, pCR at time of surgery data. * Median breast tumour volume percentage decrease, rate of breast conserving surgery, SAE rates data.